{"product_id":"clinical-immuno-oncology-hardback-9780323877633","title":"Clinical Immuno-Oncology (Hardback) 9780323877633","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eClinical Immuno-Oncology\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eUnderstand and apply recent advances in immunology to oncology therapeutics\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eJohn E. Niederhuber (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780323877633, Elsevier Health Sciences\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 9 June 2023\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e336 pages\u003cbr\u003e23.4 x 15.6 x 2.4 cm, 0.48 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eOffering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and molecular mechanisms involved in cancer initiation and progression. The text reviews the development of tumor specific antigens and the challenges of developing cancer immunotherapies. Every effort is made to relate the fundamental aspects of host immunity to the efficacy of current immunotherapies and how they work in conjunction with the immune system to combat cancer. This foundational resource explains the basics of cancer immunotherapy, discusses best practices, and provides recommendations from experienced clinicians in the field. Dr. John E. Niederhuber and a team of expert contributing authors provide clinically focused information essential for integrating these new therapies into practice—making this an ideal resource for fellows, practitioners, and other cancer team members in medical oncology, radiation oncology, cancer surgery, immunology, and cancer research.\u003cul\u003e \u003cli\u003e  \u003cp\u003eOffers balanced and synthesized content on clinical science, clinical and translational research, and evidence-based practice for cutting-edge immunotherapies. \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eDiscusses clinical applications of immunotherapies in common types of cancer including melanoma, breast cancer, pancreatic cancer, colon and rectum cancer, prostate cancer, leukemias, and hematologic malignancies. \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eIncludes dedicated chapters on immune responses, innate immunity, active immunization against cancer, and cell-based therapies by leading experts. \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eCovers key topics such as cancer immunotherapy in the presence of COVID-19, immunotherapeutics, new findings concerning the role of the microbiome in immunotherapy, advances in engineered cell-based therapies, and active immunization against cancer. \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eAn eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. \u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e   Tentative TOC:\u003c\/p\u003e \u003cb\u003e \u003c\/b\u003e\u003cp\u003eIntroduction:\u003c\/p\u003e \u003cp\u003eChapter 1.0 Development and Structure of the Lymphoid System\u003c\/p\u003e \u003col\u003e \u003col\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eembryologic development\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003egross anatomy of the human immune system\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003elymphatic endothelial cells, heterogeneity of, and lymph node microscopic structure\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003elymph node function; afferent lymph cellular components\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003erole of the gut microbiome in immune system development\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003especific functions related to the spread of cancer\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ecancer-induced lymphangiogeneis; sentinel LNs\u003c\/li\u003e \u003c\/ol\u003e\n\u003c\/ol\u003e \u003cp\u003eChapter 2.0 The Chemistry, Structure, and Function of Immunoglobulins\u003c\/p\u003e \u003col\u003e \u003col\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eimmunoglobulin isotypes\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ethe structure of immunoglobulins\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ethe genetics of immunoglobulin diversity\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eantibody-dependent cellular cytotoxicity\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eheavy-chain C domain and role of glycosylation\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ethe development of humanized monoclonals\u003c\/li\u003e \u003c\/ol\u003e\n\u003c\/ol\u003e \u003cp\u003eChapter 3.0 The Role of the Complement System in Cancer\u003c\/p\u003e \u003col\u003e \u003col\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003e\u003cb\u003ecomplement system activation pathways (classical, alternative and lectin)\u003c\/b\u003e\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ethe role of complement activation in cancer progression\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ecomplement regulatory proteins (CRPs) and cancer\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ethe role of compliment activation in the tumor microenvironment enhances tumor growth\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ecomplement-dependent cytotoxicity in immune therapy of cancer\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eformation of the membrane attack complex (MAC)\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003epotential application of anti-complement cancer therapies (C3aR\/C5aR\/IL-10 pathway)\u003c\/li\u003e \u003c\/ol\u003e\n\u003c\/ol\u003e \u003cp\u003eChapter 4.0 Cancer as Non-Self\u003c\/p\u003e \u003cp\u003e4.1 primary generator of tumor-specific transplantation type antigens \u003c\/p\u003e \u003cp\u003e4.2 character of non-self, tumor associated antigens\u003c\/p\u003e \u003cp\u003e4.3 immune surveillance – innate immunity\u003c\/p\u003e \u003cp\u003e4.4 distinguishing between self and non-self\u003c\/p\u003e \u003cp\u003e4.5 toll-like receptors (TLRs); soluble bioactive proteins such as cytokines and C’ proteins\u003c\/p\u003e \u003cp\u003e4.6 NK cells\u003c\/p\u003e \u003cp\u003eChapter 5.0 The Adaptive Immune Response in Cancer\u003c\/p\u003e \u003col\u003e \u003col\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003ethe diversity of active tumor antigen receptors\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003etarget specificity without limits in cancer-receptor variability\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003etumor antigen presentation; dendritic cells\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eimmune response stimulation against the cancer\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eCytotoxic T-cells and T-regulatory cells\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eB-cells and antibodies\u003c\/li\u003e \u003c\/ol\u003e\n\u003c\/ol\u003e \u003cp\u003eChapter 6.0 The Science of Innate Immunity\u003c\/p\u003e \u003cp\u003e6.1 critical regulator of human inflammatory disease\u003c\/p\u003e \u003cp\u003e6.2 anatomic and physiologic barriers to pathogens – cancer causing viruses\u003c\/p\u003e \u003cp\u003e6.3 centrally a limited number of critical receptors\u003c\/p\u003e \u003cp\u003e6.4 the character of the inflammatory response\u003c\/p\u003e \u003cp\u003e6.5 lack of ability to form memory\u003c\/p\u003e \u003cp\u003e6.5 role in activating subsequent adaptive immune response\u003c\/p\u003e \u003cp\u003eChapter 7.0 Immune Surveillance\u003c\/p\u003e \u003cp\u003e7.1 history of concept (Ilya Mechnikov 1908 Nobel Prize)\u003c\/p\u003e \u003cp\u003e7.2 evidence for immune surveillance today\u003c\/p\u003e \u003cp\u003e7.3 cancer in the immunocompromised host\u003c\/p\u003e \u003cp\u003eChapter 8.0 Cancer – Avoiding Immune Detection\u003c\/p\u003e \u003cp\u003e8.1 cancer and the presence of immune resistance\u003c\/p\u003e \u003cp\u003e8.2 concept for the development of tumor cell tolerance\u003c\/p\u003e \u003cp\u003eChapter 9.0 Active Immunization Against Cancer and Cell-based Therapies\u003c\/p\u003e \u003cp\u003e9.1 infusing in-vitro expanded Tumor Infiltrating Lymphocytes (TILs)\u003c\/p\u003e \u003cp\u003e9.2 infusing dendritic cells pre-loaded with tumor specific oligopeptide antigens\u003c\/p\u003e \u003cp\u003e9.3 B7 co-activating receptor\u003c\/p\u003e \u003cp\u003e9.4 vaccines\u003c\/p\u003e \u003cp\u003eChapter 10.0 The Three Major Clinical Components of Cancer Immunotherapy \u003c\/p\u003e \u003cp\u003e(modulating cell-mediated immune mechanisms)\u003c\/p\u003e \u003cp\u003e10.1 the role of and application of check point blockade\u003c\/p\u003e \u003cp\u003e10.2 the role and application of cell-based therapies including CAR-T cell therapies\u003c\/p\u003e \u003cp\u003e10.3 antibodies (and vaccines); monoclonal antibodies and novel application of bi- or tri-specifics\u003c\/p\u003e \u003cp\u003eChapter 11.0 The Clinical Application of Immunotherapeutics\u003c\/p\u003e \u003cp\u003e11.1 in melanoma cancer\u003c\/p\u003e \u003cp\u003e11.2 in breast cancer\u003c\/p\u003e \u003cp\u003e11.3 in pancreatic cancer\u003c\/p\u003e \u003cp\u003e11.4 in colon and rectum cancer\u003c\/p\u003e \u003cp\u003e11.5 in prostate cancer\u003c\/p\u003e \u003cp\u003e11.6 in leukemias and hematologic malignancies\u003c\/p\u003e \u003cp\u003e11.7 in other malignancies \u003c\/p\u003e \u003cp\u003eChapter 12.0 Cancer Immunotherapy in the Presence of COVID-19\u003c\/p\u003e \u003cp\u003e12.1 immune response to coronavirus-2 infection\u003c\/p\u003e \u003cp\u003e12.2 CD8\u003csup\u003e+ \u003c\/sup\u003eT cell depression during chronic viral infection and cancer\u003c\/p\u003e \u003cp\u003e12.3 checkpoint inhibitors in cancer patients with coronavirus infection\u003c\/p\u003e \u003cp\u003e12.4 coronavirus depletion of CD4\u003csup\u003e+\u003c\/sup\u003e T cells\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Oncology [\u003ca title=\"See our other books on Oncology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Oncology%20%5BMJCL%5D%22\"\u003eMJCL\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Elsevier","offers":[{"title":"Default Title","offer_id":46648348737816,"sku":"9780323877633","price":88.29,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9780323877633.jpg?v=1694992341","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/clinical-immuno-oncology-hardback-9780323877633","provider":"Freshly Printed Books","version":"1.0","type":"link"}